Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
Hemang Yadav, M.B.B.S., is a clinical and translational researcher who focuses on improving understanding of acute respiratory failure (ARF) and acute respiratory distress syndrome (ARDS) in the intensive care unit (ICU). Dr. Yadav's primary research focus is on improving understanding of the mechanisms of respiratory failure after hematopoietic stem cell transplantation (HCT) with the ultimate goal of developing novel ARDS prevention strategies focused on immunocompromised patients. Dr. Yadav is also studying ARF due to infections, with ongoing studies in hospitalized patients with influenza and COVID-19.
Acute respiratory distress syndrome (ARDS) is a frequent complication after HCT, dramatically influencing patient survival and quality of life. To date, effective treatments for established ARDS are few, and the impact of ARDS for individual patients can be devastating. Dr. Yadav's hope is that a better understanding of the risk factors, immunology and pathophysiology of ARDS can help identify those patients at increased risk of developing ARDS in the post-transplant period. His long-term research focus is to then develop targeted preventive strategies for high-risk individuals in order to prevent ARDS before it occurs.
Learn about clinical trials that address specific scientific questions about human health and disease.
See my studies.
Explore all research studies at Mayo Clinic.
See the peer-reviewed findings I have published as a result of my research.
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.